Assembly Biosciences (ASMB) vs Autolus Therapeutics (AUTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 0.6% versus a loss of 10.5%. Over five years, ASMB leads with a -41.7% price change compared with -71.2% for AUTL. Autolus Therapeutics is the larger company by market cap ($480.4 million vs $473.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | AUTL |
|---|---|---|
| Share price | $23.25 | $1.81 |
| Market cap | $473.30M | $480.42M |
| 1-day change | +1.87% | +1.98% |
| YTD return | -32.90% | -11.06% |
| 1-year return | -10.51% | +0.57% |
| 5-year return | -41.67% | -71.17% |
| P/E ratio (TTM) | 22.35 | — |
| EPS (TTM) | $1.04 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $2.58 |
| 52-week low | $21.80 | $1.18 |
| Distance from 52-week high | -41.46% | -30.04% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +123.69% | +383.66% |
| Average volume | 279.78K | 2.10M |
| Shares outstanding | 20.36M | 266.16M |
| Employees | 73 | 752 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed ASMB by 11.1 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
ASMB vs AUTL FAQ
Which is bigger, Assembly Biosciences or Autolus Therapeutics?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $480.42M compared with $473.30M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ASMB or AUTL?
AUTL returned +0.57% over the past 12 months, compared with -10.51% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Autolus Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Assembly Biosciences and Biotechnology: Biological Products (No Diagnostic Substances) for Autolus Therapeutics.